Compare AEON & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEON | RDI |
|---|---|---|
| Founded | N/A | 1937 |
| Country | United States | United States |
| Employees | 8 | 2005 |
| Industry | Biotechnology: Pharmaceutical Preparations | Movies/Entertainment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.8M | 23.4M |
| IPO Year | N/A | N/A |
| Metric | AEON | RDI |
|---|---|---|
| Price | $0.78 | $1.03 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.20 | N/A |
| AVG Volume (30 Days) | ★ 67.6K | 19.4K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $16.25 |
| Revenue Next Year | N/A | $4.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $0.94 |
| 52 Week High | $1.45 | $1.65 |
| Indicator | AEON | RDI |
|---|---|---|
| Relative Strength Index (RSI) | 35.97 | 41.10 |
| Support Level | $0.70 | $1.01 |
| Resistance Level | $0.82 | $1.16 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 22.00 | 6.67 |
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.